Study Summary
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Want to learn more about this trial?
Request More InfoInterventions
JCAR017GENETIC
No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival.
JCARH125GENETIC
No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| City of Hope | Duarte | California | United States |
| Massachusetts General Hospital | Boston | Massachusetts | United States |